Compare NOMD & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMD | GLUE |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2015 | 2021 |
| Metric | NOMD | GLUE |
|---|---|---|
| Price | $10.34 | $17.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $12.50 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.5M | 681.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.45 | $2.45 |
| P/E Ratio | ★ $8.38 | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $8.99 | $3.84 |
| 52 Week High | $18.33 | $25.77 |
| Indicator | NOMD | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 60.33 | 40.81 |
| Support Level | $9.47 | $17.36 |
| Resistance Level | $10.46 | $18.15 |
| Average True Range (ATR) | 0.40 | 0.98 |
| MACD | 0.10 | -0.30 |
| Stochastic Oscillator | 86.89 | 4.43 |
Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distributing branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream, and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).